Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Adin Avertising Technology Announces AI-Based Approach to Digital Media Planning - Adin.Ai

Spark Metro PR

In an era marked by challenges in transparency and efficiency, Adin.Ai disrupts the traditional media planning sector by emerging as a beacon of innovation, transforming the landscape of media planning through its AI-based advertising intelligence platform. With unparalleled precision and strategy, Adin.Ai revolutionizes planning processes across TV and digital platforms. The Visionary Team Behind Adin.Ai's Success At the helm of Adin.Ai's ground-breaking platform is an esteemed team of industry pioneers, led by the renowned entrepreneur Serhat Gurcu, a five-time honoree on the Fortune 40 Under 40 list. Partnering with Gurcu is Prof. Altan Cakır, a luminary in data science and artificial intelligence. Together with other esteemed founding partners, including visionary 2 CTOs, a PhD holder, a rising star female co-founder in media, and another female co-founder who is one of the Fast Company Female Founders for 3 years in a row, Adin.Ai stands poised at the forefront of the industry. Innovative Technology Drives Enhanced Transparency Adin.Ai's integration of AI and blockchain technology ensures an unprecedented level of transactional transparency. Through Adin.trust, each transaction is securely recorded, instilling advertisers with the confidence needed to invest in their media planning strategies. Industry Recognition and Collaborative Ventures Fast Company's recognition of Adin.Ai on both its Most Innovative Companies and Startup 100 lists underscores the company's impact. Additionally, AWS lauds Adin.Ai's proactive adoption of emerging cloud and AI technologies, particularly its utilization of generative AI, a testament to Adin.Ai's commitment to staying at the forefront of technological advancements. The collaboration between Adin.Ai and AWS engineers has resulted in a unique amalgamation of different AWS modules, harmoniously working together to enhance Adin.Ai's capabilities. With AWS's validation of its technology and an upcoming collaboration with KPMG, Adin.Ai is primed to further its influence on global media transparency. Stellar Financial Performance Foreshadows Success In its Proof of Concept (POC) year, Adin.Ai generated an impressive revenue of 300K USD, setting a robust foundation for its future endeavors. Subsequently, in its first official year, the company achieved an Annual Recurring Revenue (ARR) of 2.4M USD, alongside a Monthly Recurring Revenue (MRR) of 200K USD. Notably, 70% of this revenue was generated in Turkey, a testament to Adin.Ai's resilience amid currency fluctuations. Additionally, the company reported 11 M USD Billings in its first year, indicating strong growth and market demand for its innovative solutions. Explosive Growth in Competitive Markets Adin.Ai's strategic focus on expansion across Europe and the UK has yielded exceptional results, with a staggering 700% growth compared to the previous year. This exponential growth underscores Adin.Ai's strong business model and the burgeoning demand for innovative AI solutions in media planning. Rapid Expansion and Global Ambitions With its remarkable revenue achievements and unprecedented growth rate, Adin.Ai is poised to emerge as the preeminent interface for advertisers worldwide. The company's sights are set on further expansion and solidifying its status as a USA-established company, with Istanbul serving as the operational hub for the Europe, UK, and EMEA region, and London as the headquarters for Europe. This strategic positioning, coupled with global acclaim, sets new benchmarks for excellence in the industry. Adin.Ai is strategically positioned to shape the future of advertising, where AI-based decisions redefine the landscape. Client Success Stories Adin.Ai's transformative impact is evident through the success stories of its clients. A FINTECH company from Spain achieved a remarkable 30% reduction in Cost Per Acquisition, while the largest private bank in Turkey witnessed a substantial 70% increase in Viewability. Additionally, a fashion company from the UK experienced a significant 64% boost in Return on Ad Spend (ROAS), and a gaming company from the Netherlands successfully mitigated display ad fraud by 52%. These results underscore Adin.Ai's commitment to driving tangible outcomes for its clients across diverse industries. Adin.Ai as the AI-Based Digital Advertising Platform for Enterprise Advertisers: Maximize Ad Return up to 5X; Minimize Effort up to 100X. With Adin.Ai, advertisers gain access to a cutting-edge platform that maximizes ad returns up to 5 times while minimizing effort up to 100 times. Our revolutionary AI-driven approach to digital media planning empowers advertisers to achieve unparalleled success in their campaigns. For further insights into Adin.Ai's journey and services, visit www.adin.ai Founders of the Company: Serhat Gürcü: LinkedIn Profile Prof. Altan Çakır: LinkedIn Profile Selin Ergin: LinkedIn Profile Halil Faruk Deniz: LinkedIn Profile Özgün Akın: LinkedIn Profile Seden Gürcü: LinkedIn Profile SOURCE: Adin.Ai Contact Details Adin.ai Seden Gurcu +90 533 476 96 49 Seden@adin.ai Company Website https://adin.ai/

March 26, 2024 11:08 AM Eastern Daylight Time

Image

Tennr puts fax machines back in vogue for healthcare organizations using AI, as it secures $18m from a16z

Tennr

Fax machines are older than telephones and the internet. Despite being a legacy technology, the healthcare industry still sends 9 billion faxes a year because they are more reliable than telephone calls and emails. While most startups have been trying to digitize faxes out of existence, Tennr has raised $18M to bridge healthcare’s problems in an unconventional way: working with, not against, the fax machine. Tennr’s $18m series A funding round was led by a16z with participation from Foundation Capital and The New Normal Fund. Other investors (from the seed round) include YCombinator, Zaza Pachulia, Jennifer Kaehms, and other notable health and AI focused investors. With this funding round, Tennr has now raised over $25m. Tennr’s founders, Trey Holterman, Diego Baugh, and Tyler Johnson, met as freshmen at Stanford where they worked together studying machine learning. They saw early on how good contextual models were becoming at doing repetitive, manual tasks and how much power this had to ‘magic away’ busywork in traditional industries. After graduation, the team dedicated years to building powerful, robust systems for reading unstructured documents, automating data entry, and applying them specifically to healthcare. Today, practices nationwide are using Tennr to automate referral processing, payment posting, claims auditing, medical record management and more. Many thought faxes would face their end in 2009 when the HITECH Act put $27 billion towards encouraging healthcare to use EHRs, become “paperless,” and set up integrations. Fifteen years later, most providers and hospitals have implemented EHRs, but still default to e-faxing for sending or receiving patient records, audit requests, and referrals back to coordinate patient care. This manual work triggers an endless cascade of issues for practices: it’s time-consuming, takes longer for patients to receive critical care, is vulnerable to human error, leads to expensive claim denials, creates needless back-and-forth between practices delaying care, and increases employee burnout and turnover. While most products that streamline healthcare workflows attempt to sever the dependency on faxes, Tennr is taking a different approach. Instead of expecting practices to change, Tennr meets them where they are — working inside the solution they already know and trust. When a practice receives a digital fax through email or their EHR inbox, Tennr reads the documents and automates the work associated with processing them. This act of finding and moving information quicker and with more accuracy resolves most of the problems digital faxes cause. For example, when a patient is referred from a primary care provider to a specialty practice through a faxed referral, Tennr, in real time, extracts the key patient information and coordinates with the patient so they can be scheduled quickly and accurately; if a fax or referral is incomplete, Tennr automatically requests the missing information. As a result, patients get the care they need, allowing practices to maintain stronger referral relationships, provide continuity of care and improve patient outcomes. “When building Tennr and this healthcare integration, we looked at what’s actually needed and saw what was possible with technology. Our number one integration today is across fax providers, on-prem file storage systems and EHRs from the 90s. And this is the real life need of the industry. But beyond that, what people miss the most in all of this is that it’s not about just automating work or making teams faster. Lots of people can build tools that make admins marginally faster–that just doesn’t move the needle. Instead, our research team is building models based around this very complex information flow, being able to parse it for one practice at a time, and then do the work so well that you can turn it into very clear growth for a business. And yes, the e-fax ends up being in the middle of it all,” said Trey Holterman, CEO and co-founder of Tennr. Insurance denials are often the result of poor or unclear information which impacts the provider and patient. Tennr works on both sides of the insurance/provider relationship, automating the flow of information to commercial payors, as well as reading the information that’s returned. Ultimately, this helps service providers catch and correct wrong information before they submit to a commercial payor. Moreover, when Tennr identifies wrong information it’s able to request the correct information, in the correct format – minimizing insurance denials and helping practices get paid faster. And since Tennr is automating this work, there are no manual errors, less employee burnout, and crucially, returns time back to staff. The hard part is of course, actually reading the faxes, and integrating with archaic systems. Documents that can be many pages long with dozens of patients attached are unstructured, messy blobs of data that are nearly impossible for computers to work with. To make matters worse, actually getting data where it needs to go (onto an electronic health records system) requires maintaining integrations with archaic and fragmented systems. Rommy Foteh, the Chief Operations Officer at NMA, a national specialty practice serving tens of thousands of patients a month said: “it's been about effectively seeing more patients while being the kind of partner our customers need. When we’re able to respond to our partners as quickly as we do now using Tennr, and ensure we have everything we need to see a patient, those patients remember their great experience with NMA, encouraging our surgeons and hospitals to continue to refer to us.” Commercial health plans like Prominence Health have begun to excitedly embrace this new technology as well, seeing it as a driver for better experiences for providers which means a better experience for patients subscribed to Prominence Health. Dominic Henriquez, Chief Development Officer at Prominence Health said, “At Prominence Health, we lead the charge in innovating value-based care, constantly seeking disruptive technologies to enhance operational efficiency. The Tennr product seamlessly aligns with our mission to deliver higher value to our customers. By eliminating traditional administrative burdens like scanning medical records and data entry, Tennr enables us to prioritize elevating patient experiences, improving health outcomes, and enhancing care coordination.” Cleaning up the messy data coming in from faxes to automate patient intake and insurance communications is just the beginning of Tennr’s vision. If Tennr can read faxes, understand what information needs to be extracted from them, and where that information needs to go, it can chip away at many of the most costly problems within the US health system. For now, Tennr is using this investment to grow its team, scale its operations, and help organizations automate everything that starts with a fax. “Amidst the theoretically unbounded possibilities of AI, the Tennr team has impressed us with their unwavering focus on building applications solving specific, tangible problems for their customers, said Kristina Shen, general partner at Andreessen Horowitz. About Tennr Based in New York, Tennr automates the messy, painful, manual work holding healthcare organizations back from seeing more patients, increasing revenue, and growing their business. These automations are configurable to the intricacies of each organization’s workflows – meaning they can perform exactly the way a human would, using a practice’s existing tools. As a result, organizations can automate any work that begins with a fax without migrating to a new tool or increasing their headcount. These organizations can also use the data Tennr structures to take advantage of trends that can grow their practice. Learn more at https://www.tennr.com/ About a16z Andreessen Horowitz (aka a16z) is a venture capital firm that backs bold entrepreneurs building the future through technology. We are stage agnostic. We invest in seed to venture to growth-stage technology companies, across AI, bio + healthcare, consumer, crypto, enterprise, fintech, games, and companies building toward American dynamism. a16z has $35B in assets under management across multiple funds. Contact Details Tennr Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.tennr.com/

March 26, 2024 09:00 AM Eastern Daylight Time

Image

Classiq Advances the HPC Quantum Computing Stack by Integrating Classiq’s Engine with NVIDIA CUDA-Q

Classiq Technologies

Classiq, a leader in quantum computing software, today announced it is integrating Classiq’s software with the NVIDIA CUDA-Q platform, which was announced by NVIDIA at its GTC conference last week. This integration facilitates a streamlined process for researchers working with CUDA-Q to generate, analyze and execute quantum circuits. It supports a wide range of quantum applications, including simulations and machine learning. The Classiq true compilation technology enables quantum circuit synthesis that automates the implementation of quantum programs. This capability enables the development process for quantum software and ensures that the generated programs are finely tuned for execution on a broad range of quantum hardware, as well as NVIDIA GPUs. Previously, NVIDIA, Rolls Royce and Classiq demonstrated a breakthrough in quantum computational fluid dynamics (CFD) by designing and simulating the largest quantum program to date. Classiq also launched a Quantum Computing for Life Sciences & Healthcare Center in collaboration with NVIDIA. “Classiq’s technology lies at the heart of quantum computing and provides a powerful conduit between high-performance computing (HPC) users and quantum computing implementation,” said Nir Minerbi, CEO of Classiq. “We’re well-known for our popular quantum development platform, and this integration demonstrates Classiq’s focus on ensuring today’s CUDA-Q and HPC users benefit from seamless access to automatic production of optimized quantum and hybrid quantum-classical algorithms.” Classiq is leveraging its technology to bridge HPC and quantum computation. From simulation to deploying hybrid quantum-classical algorithms to enhanced data processing, this convergence is accelerating as the two advanced computation sectors grow closer. Classiq provides the ideal combination of libraries, functions and automation to support this hybrid HPC-quantum computation space. HPC and quantum computing are increasingly connected through the deployment of hybrid algorithms, co-location of hardware and an emerging talent pool of expert hybrid developers. Classiq makes quantum computing tools more accessible to the global research community, addressing the need to tackle complex problems across various domains such as healthcare, materials science, engineering and finance. Meet Classiq next at the International Supercomputing 2024 conference running May 12-16th in Hamburg, Germany. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking users from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, join the Slack community, or try the Classiq platform. Contact Details Rainier Communications Michelle Allard McMahon +1 781-718-3248 classiqPR@rainierco.com Company Website http://www.classiq.io/

March 26, 2024 08:00 AM Eastern Daylight Time

NAVEX 2024 Global Incident Management Benchmark Study Reveals Significant Third-Party Reporting to Companies

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, has released its 2024 Whistleblowing & Incident Management Benchmark Report. The annual benchmark report offers valuable insights into workplace culture, analyzing trends from 1.86 million global reports spanning thousands of organizations that together employ more than 50 million employees. Amid a record number of tips to the SEC and a burgeoning DOJ whistleblowing program, NAVEX’s comprehensive analysis sheds a critical light on the state of workplace environments worldwide, guiding organizations toward program improvement. "NAVEX remains the gold standard in risk and compliance data analytics, continually innovating our benchmarks to enhance corporate compliance programs and offer business leaders insights into the trending risk areas for their organizations," says NAVEX Chief Risk and Compliance Officer Carrie Penman. "This year's report introduces crucial third-party reporting insights, highlighting an organization’s need to adopt internal and external reporting avenues to bolster integrity, foster accountability and equip the organization to tackle emerging challenges effectively.” This year’s analysis of the data revealed several key themes and notable findings, including: Report volume and case substantiation reach milestones. Internal reporting programs saw a record level of use as measured by NAVEX’s Reports per 100 Employees metric. In addition, the Substantiation Rate metric reached an all-time high, meaning more reports were received and more were found to be true. Report volume, and the substantiation rates of the reports received, are two of the most highly watched metrics in the annual NAVEX publication. To see both reach the highest levels ever is good news. For those with trusted and effective internal reporting programs, this added up to greater visibility into the trends of risk, ethics and culture playing out in their organizations’ operations – real-time intelligence to inform business decision-making. In 2023, organizations received a median 1.57 Reports per 100 Employees across their internal reporting systems, exceeding the previous record of 1.47 set in 2022. More organizations (23%) received five or more Reports per 100 Employees, making this population the largest in the NAVEX data set. And while year-over-year values fluctuated, every size of organization – from the smallest companies to enterprises with over 100,000 employees – has seen report volumes rise comparing 2021 and 2023. At 45%, the overall median share of substantiated or founded reports in 2023 reached an 11-year high. Third parties more likely to report business integrity and financial misconduct issues. In a first for this report, NAVEX analyzed its database by both employees and third-party reporters. Its analysis shows these two groups are distinct across several metrics, highlighting the insight organizations see by promoting their reporting programs internally and externally. Third parties as a group delivered a far greater median share of reports related to Business Integrity matters than employees in 2023 (50% versus 17%). Encompassing topics like conflicts of interest, vendor issues, fraud, global trade and human rights, this category of issues can manifest in various elements of a supply chain. Third-party reporters also showed twice the median share of Accounting, Auditing & Financial Reporting reports as employees in 2023 (10% versus 4.5%). Story emerging on accounting-related reporting – internally and externally. Accounting-related reports -- while lower in overall percentage of reports received internally by organizations at a median of 4.3.% in 2023 -- often receive an outsized share of attention due to potential for regulatory action and the well-publicized bounty program offered by the SEC and its Office of the Whistleblower. The SEC's program is witnessing unprecedented growth in tips and generously rewarding valuable information. Now, the U.S. Department of Justice is launching a similar initiative. Specifically, reports related to Accounting, Auditing, and Financial reporting: Showed the longest time between when an incident was observed and when it was reported to the organization By a large margin, were least likely to be reported anonymously Comprised an outsized share of cases for organizations that receive very few Reports per 100 Employees – meaning while these organizations received well below the benchmark number of reports, they had a much more significant percentage of accounting-related reports Experienced the longest time to investigate and close the case Had among the highest median Substantiation Rates, at 50% Were most likely to cause an employment separation event as a result of a substantiated case Accounted for twice as many of the reports submitted by third parties than those submitted by employees Small increase in report volume shows big payoff in healthy report mix. A diverse array of topics, inquiries, and allegations in internal reporting indicates a robust program. NAVEX’s findings reveal that even minor efforts to promote internal reporting significantly improve the mix of report types received. For instance, in organizations with the lowest report volume, only 8.7% of reports pertain to HR, Diversity, and Workplace Respect. However, in the next tier, this proportion jumps to 36.3%. This trend persists across different report volumes, emphasizing the importance of fostering a reporting culture. A varied mix of report types signifies trust in internal reporting to address a broad spectrum of issues. Even a slight increase from minimal reporting yields a more comprehensive and insightful flow of reports. "With NAVEX's integrated data platform, companies gain unparalleled risk signal data that empowers them to foster healthier workplace cultures, helping them achieve outcomes that matter most,” explains NAVEX Chief Product Officer A.G. Lambert. "Data isn't just numbers; it's the compass guiding organizations toward success and ensuring they stay ahead in the ever-evolving landscape of risk and compliance." Additional notable findings include: Workplace behaviors and discord were clearly visible in the data as more organizations return to office environments. As is always the case in these reports, workplace behaviors and other human resources related matters are by far the highest percentage of reports received by organizations. Workplace Civility matters continued to increase in prominence in 2023, representing a median of 18% of reports and the highest median reporting rate in 2023. This was followed by Discrimination, at a median 12%, Harassment, at a median 7.1%, then Retaliation at a median of 2.0%. The HR, Diversity and Workplace Respect category overall has seen a multi-year increase in its median share of all reports (from 50% in 2021 to 55% in 2023). These figures underscore the growing importance of fostering a respectful and inclusive work environment. Highlighting the seriousness with which organizations are taking reports received, more substantiated reports (18%) resulted in separation from employment in 2023, up significantly from 14% in 2022 and 12% in 2021. The share of reports resulting in no action – effectively the opposite end of the outcome spectrum – fell from 17% in 2022 to 14% in 2023. Nearly nine out of 10 reports of Imminent Threat to a Person, Animals or Property were substantiated in 2023 highlighting the importance that reporters possess the training, knowledge, tools and trust that promote rapid reporting of dangerous issues. This need is made even greater by a new California workplace violence prevention law expected to take effect this year that includes requirements for reporting, incident management and training around this issue. For more insights on the 2024 Whistleblowing & Incident Management Benchmark Report, join Jane Norberg, Arnold & Porter partner and former chief of the SEC Office of the Whistleblower, Keith Thomas, FedEx corporate integrity & compliance lead counsel, Carrie Penman, NAVEX chief risk & compliance officer, and Anders Olsen, NAVEX senior data scientist, for an informative webinar where they will discuss the results of this year’s analysis in detail. Watch the webinar here. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global scott.levesque@navex.com Company Website https://navex.com

March 26, 2024 06:00 AM Eastern Daylight Time

An Inherited Condition Could be the Cause of Your Early Heart Disease or Stroke, But Your Doctor is Probably Not Testing for It

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/Y_mu9ZpIO88 Heart disease is still the single biggest threat to American health today. Family Heart Foundation research shows that less than 5% of Americans are being screened for the most common, life-threatening genetic condition that causes early strokes and heart attacks – elevated Lipoprotein(a) or Lp(a) for short. Elevated lipoprotein(a) is the most common genetic cause of early heart disease and stroke. One in 5 people worldwide have inherited high Lp(a), and most don’t know it. You inherit your Lp(a) level from your parents. Because elevated Lp(a) isn’t screened for, the first sign of this condition may be a stroke or a heart attack. Elevated levels of Lp(a) increases the risk of blood clotting and plaque buildup inside the blood vessels, which can block the flow of blood and oxygen to your heart and brain. Compared to the general population, people with elevated Lp(a) have 2-3 times the risk for a heart attack and stroke at a young age. The higher your Lp(a), the higher your risk. Lp(a) is not measured in the standard cholesterol panel. It’s important to understand if you have elevated Lp(a). Multiple therapies are in development but in the meantime, there are things you can do to manage your other cardiovascular risk factors, such as keeping your LDL cholesterol levels very low. The Family Heart Foundation can help you find a healthcare provider near you and connect you to others living with elevated Lp(a). The Family Heart Foundation is the only patient-centered, research and advocacy organization focused on addressing the lack of screening and care for people born and living with this common life-threatening condition. On March 20 th a nationwide media tour was conducted featuring Dr. Amit Khera, Professor and Director of Preventive Cardiology UT Southwestern Medical Center and Misty Votaw. Topics they discussed included: Who should have their Lp(a) measured and when. Misty’s story and how the Family Heart Foundation provided resources. If you have elevated Lp(a), what can you do to reduce your risk of heart disease and stroke. What the Family Heart Foundation is doing to address gaps in care for 60 million Americans at risk. For more information and to find out if you have elevated Lp(a), contact the Family Heart Foundation’s Care Navigation team at FindLpa.org. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 25, 2024 01:13 PM Eastern Daylight Time

Video

AGC Biologics Strengthens Executive Leadership with Appointment of Dr. Christoph Winterhalter as Chief Business Officer

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the promotion of Dr. Christoph Winterhalter to Chief Business Officer and a new member of the executive leadership team. Winterhalter, who has three decades of experience in the biopharmaceutical industry, will oversee corporate strategy, business development, new business initiatives and global marketing for the AGC Biologics CDMO network. He has a strong track record of success within the Life Science industry, including creating strategies for sustainable and profitable business growth, building and maintaining highly motivated and skilled global teams, leading business development and marketing initiatives and developing strategic partnerships with large pharma and biopharmaceutical companies. Winterhalter previously served as the Senior Vice President Business Development EMEA for AGC Biologics. “Throughout his career, Christoph has developed a unique combination of technical knowledge and the ability to create business growth for life science organizations. I am pleased to appoint him to this new position,” said Patricio Massera, CEO, AGC Biologics. “He is a proven leader with a vision that knows how to create value for our business through corporate development, strategic partnerships, and sales and marketing initiatives. This experience will be crucial for AGC Biologics’ growth, and I am confident he will positively impact our global teams as we strive to achieve our purpose: to bring hope to life by enabling life-changing therapies for patients around the globe.” Winterhalter joined AGC Biologics in 2018 and contributed significantly to the company’s growth over the past six years. Before that, he served as the Senior Vice President of Global Business Development for the CDMO Rentschler Biopharma. Reporting directly to the CEO, he guided the company’s global sales and development strategy and created strategic manufacturing alliances with leading global biopharmaceutical companies. While at Rentschler, he was instrumental in tripling the top-line sales numbers for the company. Before that, Winterhalter worked at Wacker Chemie AG supporting its Life Science businesses for nearly 20 years, most recently serving as Vice President of Biosolutions for the Americas. At Wacker he managed teams focused on Research and Development (R&D), Project Management, GMP Production, Business Development, and Marketing. Winterhalter received a degree in Microbiology and his Doctorate from the Technical University of Munich. "I am enthusiastic to be taking more responsibility with this position at a company dedicated to supporting biopharmaceutical companies developing important treatments to help patients worldwide," said Christoph Winterhalter, CBO, AGC Biologics. "I look forward to partnering with the rest of the executive team, contributing my expertise to advance AGC Biologics’ business goals, and working side-by-side with our partners to bring their innovative biopharmaceuticals all the way to market." To learn more about AGC Biologics and its global CDMO services visit www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs ten different facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

March 25, 2024 01:09 PM Eastern Daylight Time

ECO Animal Health focused on innovation and global expansion as it grows its pipeline

Eco Animal Health Group PLC

ECO Animal Health Group PLC CEO David Hallas joins Proactive's Stephen Gunnion with more on the global animal health company focused on pigs and poultry. Hallas explained the company offers a variety of products aimed at maintaining animal health and treating diseases, particularly respiratory and intestinal issues. While a significant portion of its revenue is attributed to its flagship product, Aivlosin, he said the company maintains a diversified portfolio with operations in over 70 countries, more than 20 products, and around 200 licences for different indications. Hallas highlighted the company's fourth-quarter and full-year 2024 trading performance, driven by increasing demand for its products, especially Aivlosin, which assists in raising healthy animals to meet the global protein demand. The company's growth is notably robust in Brazil, a key protein producer. Hallas clarified that the company's operations and revenue are not overly dependent on China, with over 75% of revenue generated from outside this region. Despite challenges in the Chinese market reported by competitors, Hallas differentiates ECO Animal Health's sector from genetics, emphasizing its focus on animal health and prevention. The company is also expanding its product line with the upcoming launch of vaccine products in 2025, following recent trademark approvals in the EU, UK, and the US. Additionally, ECO Animal Health has initiated a limited share buyback, viewing it as an opportunistic use of funds following property disposals, while still prioritizing investments in innovation and the current business. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 21, 2024 12:26 PM Eastern Daylight Time

Video

Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month

Immunic Inc

Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month, highlighting the disease's impact, development, and the unmet medical needs of patients. MS, a lifelong autoimmune disease more prevalent in women than men, begins typically in early adulthood. It manifests in various forms, starting with relapsing-remitting MS, characterized by relapses and MRI lesions, affecting 80-85% of patients. Another form, primary progressive MS, occurs in 10-15% of patients, starting with a progressive phase without typical relapses. As the disease advances, Muehler explained that it transitions into secondary progressive MS, marked by a decrease in relapses but an increase in disability, which is a significant concern for patients. Despite the availability of treatments focusing on inflammation, there remains a significant gap in addressing the disability progression, a key area of concern for patients. Muehler introduced Immunic Inc's approach to tackling MS through their drug, vidofludimus calcium (IMU-838), which possesses dual mechanisms: anti-inflammatory and neuroprotective. The neuroprotective aspect, in particular, is believed to address the critical unmet need of slowing disability progression by protecting neurons. This differentiation, especially in progressive MS where current therapies fall short, positions vidofludimus calcium as a promising candidate in the MS treatment landscape. Clinical trials for vidofludimus calcium are underway, with a notable Phase 2 study, CALLIPER, fully enrolled and expected to read out in April 2025. Additionally, Phase 3 studies in relapsing MS are actively recruiting, with outcomes anticipated in 2026. These developments are keenly awaited by the medical community and potential partners, given the drug's potential to significantly impact MS treatment, particularly for forms of the disease currently lacking effective therapies. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 21, 2024 12:14 PM Eastern Daylight Time

Video

PainChek leads innovation in AI-based pain assessment

PainChek Ltd

PainChek Ltd (ASX:PCK), a medical device company, is pioneering the use of an app, leveraging artificial intelligence (AI) for pain assessment in vulnerable individuals unable to communicate their pain due to conditions such as dementia, cognitive impairments, or in pre-verbal children. In and interview with Proactive's Stephen Gunnion CEO and managing director Philip Daffas highlighted that PainChek's app is the world's first regulatory-cleared medical device for this purpose. It utilises AI for facial analysis to detect nine micro facial features indicative of pain, assisting carers in aged care and hospitals to document and score the severity of pain. PainChek has achieved a first mover advantage with patents in the US, Europe, Japan, and the UK, protecting its technology until 2038. The company has regulatory clearance in Australia, New Zealand, Canada, the UK, the EU, Singapore, and Malaysia, with ongoing clinical studies in the US aimed at FDA clearance. PainChek reported its fifth consecutive quarter of double-digit growth in the December quarter, with 85,000 licences across 1,400 aged care facilities on three continents. With an annual recurring revenue of around $4 million, the company sees a significant growth opportunity in aged care, home care, and the hospital sector. Key milestones for investors include expansion in regulatory-cleared markets, entry into the US market upon FDA clearance, and the launch of an infant app for pain assessment in the home. Contact Details Proactive Australia Pty Ltd Proactive Australia Pty Ltd +61 431 597 771 writers.australia@proactiveinvestors.com

March 21, 2024 12:07 PM Eastern Daylight Time

Video

1 ... 43 44 45 46 47 ... 300